Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSI NASDAQ:NAGE NASDAQ:NKTX NASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.42+6.4%$1.60$1.18▼$2.44$55.51M0.4327,553 shs19,964 shsNAGENiagen Bioscience$3.35+1.7%$3.59$3.17▼$11.58$266.81M2.091.00 million shs6,186 shsNKTXNkarta$2.63-0.8%$2.93$1.70▼$3.72$188.51M0.9774,094 shs2,321 shsSRZNSurrozen$22.05+0.8%$25.27$8.20▼$35.00$260.98M0.51176,793 shs226,204 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring0.00%-19.88%-15.29%-21.35%-41.92%NAGENiagen Bioscience-5.19%-4.64%-4.64%-30.59%-70.78%NKTXNkarta-5.02%-21.60%-7.34%+9.50%+40.21%SRZNSurrozen-4.08%-4.91%-6.46%-31.67%+154.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.42+6.4%$1.60$1.18▼$2.44$55.51M0.4327,553 shs19,964 shsNAGENiagen Bioscience$3.35+1.7%$3.59$3.17▼$11.58$266.81M2.091.00 million shs6,186 shsNKTXNkarta$2.63-0.8%$2.93$1.70▼$3.72$188.51M0.9774,094 shs2,321 shsSRZNSurrozen$22.05+0.8%$25.27$8.20▼$35.00$260.98M0.51176,793 shs226,204 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring0.00%-19.88%-15.29%-21.35%-41.92%NAGENiagen Bioscience-5.19%-4.64%-4.64%-30.59%-70.78%NKTXNkarta-5.02%-21.60%-7.34%+9.50%+40.21%SRZNSurrozen-4.08%-4.91%-6.46%-31.67%+154.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 1.00SellN/AN/ANAGENiagen Bioscience 3.00Buy$10.50213.81% UpsideNKTXNkarta 2.83Moderate Buy$10.75308.75% UpsideSRZNSurrozen 2.50Moderate Buy$42.0090.48% UpsideCurrent Analyst Ratings BreakdownLatest BYSI, NAGE, SRZN, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026NAGENiagen Bioscience Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/1/2026NAGENiagen Bioscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/29/2026SRZNSurrozen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/24/2026NKTXNkarta Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026NKTXNkarta TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/11/2026NAGENiagen Bioscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/7/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00 ➝ $44.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.75M33.25$0.12 per share11.70($0.59) per share-2.40NAGENiagen Bioscience$130.42M2.04$0.20 per share17.11$0.96 per share3.49NKTXNkartaN/AN/AN/AN/A$4.40 per shareN/ASRZNSurrozen$3.48M73.56N/AN/A($19.21) per share-1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$1.01M-$0.14N/AN/AN/AN/AN/A-14.00%8/12/2026 (Estimated)NAGENiagen Bioscience$17.38M$0.2115.9511.15N/A14.29%22.68%16.23%N/ANKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)SRZNSurrozen-$242.03M-$37.59N/AN/AN/A-4,810.50%N/A-154.08%8/14/2026 (Estimated)Latest BYSI, NAGE, SRZN, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026BYSIBeyondSpring-$0.54N/AN/AN/A$8.77 millionN/A8/11/2026Q2 2026NKTXNkarta-$0.39N/AN/AN/AN/AN/A5/13/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A5/6/2026Q1 2026NAGENiagen Bioscience$0.06$0.07+$0.01$0.07N/A$31.47 million5/6/2026Q1 2026SRZNSurrozen-$1.0920-$11.65-$10.5580-$11.65$4.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A1.091.09NAGENiagen BioscienceN/A4.613.55NKTXNkartaN/A12.9612.96SRZNSurrozenN/A11.9111.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%NAGENiagen Bioscience15.41%NKTXNkarta80.54%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%NAGENiagen Bioscience10.00%NKTXNkarta9.80%SRZNSurrozen31.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableNAGENiagen Bioscience12079.64 million71.68 millionN/ANKTXNkarta14071.54 million64.53 millionOptionableSRZNSurrozen8011.61 million7.93 millionNot OptionableBYSI, NAGE, SRZN, and NKTX HeadlinesRecent News About These Companies5AM Venture Management LLC Buys 77,500 Shares of Surrozen, Inc. $SRZNJune 18, 2026 | marketbeat.comSurrozen (SRZN) Stock Forecast & Price TargetJune 4, 2026 | investing.comWe're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn RateMay 17, 2026 | finance.yahoo.comSurrozen (SRZN) price target increased by 10.11% to 43.52May 14, 2026 | msn.comSurrozen Shareholders Support Board, Auditor and Pay PoliciesMay 14, 2026 | tipranks.comSurrozen to Present at Upcoming Healthcare Investor ConferenceMay 12, 2026 | globenewswire.comSurrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comInsider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,584 Shares of StockMay 6, 2026 | insidertrades.comSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28, 2026 | globenewswire.comTD Cowen initiates coverage of Surrozen (SRZN) with buy recommendationApril 23, 2026 | msn.comSurrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?April 14, 2026 | zacks.comLifeSci Capital Keeps Their Buy Rating on Surrozen (SRZN)March 29, 2026 | theglobeandmail.comSurrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Purchases 15,223 SharesMarch 26, 2026 | insidertrades.comTCG crossover funds buys Surrozen (SRZN) shares worth $3mMarch 25, 2026 | investing.comSurrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 23, 2026 | globenewswire.comTcg Crossover Gp Ii, Llc Acquires 1,190 Shares of Surrozen (NASDAQ:SRZN) StockMarch 17, 2026 | insidertrades.comTCG Crossover funds buys Surrozen (SRZN) shares worth $1.2mMarch 16, 2026 | investing.comSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 23, 2026 | globenewswire.comCantor Fitzgerald initiates coverage of Surrozen (SRZN) with overweight recommendationFebruary 19, 2026 | msn.comInsider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys 1,093 Shares of StockFebruary 14, 2026 | insidertrades.comSurrozen (SRZN) price target increased by 13.51% to 42.84February 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Waste Stocks Turning AI Investments into GrowthBy Chris Markoch | June 27, 2026Dividend Increases: From Over 10% Yields to Over 10% Dividend GrowthBy Leo Miller | June 24, 20263 Non-Pharma Firms That Could Benefit From the GLP-1 TrendBy Nathan Reiff | June 20, 2026onsemi: What the Market Gets Wrong, You Can Get RightBy Thomas Hughes | June 29, 2026Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity YetBy Thomas Hughes | July 14, 2026BYSI, NAGE, SRZN, and NKTX Company DescriptionsBeyondSpring NASDAQ:BYSI$1.42 +0.09 (+6.39%) As of 09:42 AM Eastern This is a fair market value price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Niagen Bioscience NASDAQ:NAGE$3.35 +0.06 (+1.70%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Nkarta NASDAQ:NKTX$2.63 -0.02 (-0.75%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Surrozen NASDAQ:SRZN$22.05 +0.17 (+0.78%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
